Physician profile
Matthew Robison
NPI 1194757393
$1,820.69
in general payments reported to CMS, 2019-2025
15 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.04 · 2020: $34.37 · 2021: $82.59 · 2022: $202 · 2023: $109 · 2024: $145 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $973 · Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $973.19 |
| Food and Beverage | $503.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,074.04 | 2025 | Interstim |
| Abbvie INC. | $234.83 | 2020-2025 | Liletta |
| Astellas Pharma US INC | $232.61 | 2022-2025 | Veozah |
| Daiichi Sankyo INC. | $44.47 | 2020-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $41.22 | 2022-2023 | |
| Coloplast Corp | $30.16 | 2021 | |
| Exeltis, USA INC. | $28.55 | 2022 | |
| Sumitomo Pharma America, INC. | $26.54 | 2025 | Myfembree |
| Amgen INC. | $25.96 | 2019-2022 | |
| Therapeuticsmd, INC. | $25.02 | 2019-2021 | |
| Shield Therapeutics INC | $16.93 | 2024 | |
| Novo Nordisk INC | $14.38 | 2025 | Wegovy |
| Bioventus LLC | $13.32 | 2023 | |
| Lilly USA, LLC | $12.66 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.